TY - JOUR
T1 - High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada
T2 - findings from over two decades (1991–2010)
AU - Kingwell, Elaine
AU - Zhu, Feng
AU - Marrie, Ruth Ann
AU - Fisk, John D.
AU - Wolfson, Christina
AU - Warren, Sharon
AU - Profetto-McGrath, Joanne
AU - Svenson, Lawrence W.
AU - Jette, Nathalie
AU - Bhan, Virender
AU - Yu, B. Nancy
AU - Elliott, Lawrence
AU - Tremlett, Helen
N1 - Funding Information:
This study was supported by the Canadian Institutes of Health Research (CIBG 101829); the Rx&D Health Research Foundation; and a Don Paty Career Development Award from the MS Society of Canada (to RAM). We thank the BC Ministry of Health, BC Vital Statistics Agency and BC PharmaNet for approval and support with accessing provincial data; and Population Data BC for facilitating approval and use of the data.
Funding Information:
Dr. Yu receives research funding from: Health Science Centre Foundation, Canadian Institutes of Health Research, Gilead Sciences, Canadian International Development Agency, Multiple Sclerosis Society of Canada, and National Multiple Sclerosis Society.
Funding Information:
Dr. Marrie receives research funding from: Canadian Institutes of Health Research, Public Health Agency of Canada, Manitoba Health Research Council, Health Sciences Centre Foundation, Multiple Sclerosis Society of Canada, Multiple Sclerosis Scientific Foundation, Rx&D Health Research Foundation, and has conducted clinical trials funded by sanofi-aventis.
Funding Information:
Dr. Jette is the holder of a Canada Research Chair in Neurological Health Sciences and an Alberta Innovates Health Solutions (AI-HS) Population Health Investigator Award. She receives research funding from the Canadian Institutes of Health Research, AI-HS, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Alberta Health Services and Alberta Health.
Funding Information:
Dr. Wolfson receives funding from: Canadian Institutes of Health Research, Canada Foundation for Innovation, Multiple Sclerosis Society of Canada, National Multiple Sclerosis Society, Research Institute of the McGill University Health Centre.
Funding Information:
Dr. Warren receives funding from Canadian Institutes of Health Research and Fort Assiniboine Equine Endeavour Foundation.
Publisher Copyright:
© 2015, The Author(s).
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Province-wide population-based administrative health data from British Columbia (BC), Canada (population: approximately 4.5 million) were used to estimate the incidence and prevalence of multiple sclerosis (MS) and examine potential trends over time. All BC residents meeting validated health administrative case definitions for MS were identified using hospital, physician, death, and health registration files. Estimates of annual prevalence (1991–2008), and incidence (1996–2008; allowing a 5-year disease-free run-in period) were age and sex standardized to the 2001 Canadian population. Changes over time in incidence, prevalence and sex ratios were examined using Poisson and log-binomial regression. The incidence rate was stable [average: 7.8/100,000 (95 % CI 7.6, 8.1)], while the female: male ratio decreased (p = 0.045) but remained at or above 2 for all years (average 2.8:1). From 1991–2008, MS prevalence increased by 4.7 % on average per year (p < 0.001) from 78.8/100,000 (95 % CI 75.7, 82.0) to 179.9/100,000 (95 % CI 176.0, 183.8), the sex prevalence ratio increased from 2.27 to 2.78 (p < 0.001) and the peak prevalence age range increased from 45–49 to 55–59 years. MS incidence and prevalence in BC are among the highest in the world. Neither the incidence nor the incidence sex ratio increased over time. However, the prevalence and prevalence sex ratio increased significantly during the 18-year period, which may be explained by the increased peak prevalence age of MS, longer survival with MS and the greater life expectancy of women compared to men.
AB - Province-wide population-based administrative health data from British Columbia (BC), Canada (population: approximately 4.5 million) were used to estimate the incidence and prevalence of multiple sclerosis (MS) and examine potential trends over time. All BC residents meeting validated health administrative case definitions for MS were identified using hospital, physician, death, and health registration files. Estimates of annual prevalence (1991–2008), and incidence (1996–2008; allowing a 5-year disease-free run-in period) were age and sex standardized to the 2001 Canadian population. Changes over time in incidence, prevalence and sex ratios were examined using Poisson and log-binomial regression. The incidence rate was stable [average: 7.8/100,000 (95 % CI 7.6, 8.1)], while the female: male ratio decreased (p = 0.045) but remained at or above 2 for all years (average 2.8:1). From 1991–2008, MS prevalence increased by 4.7 % on average per year (p < 0.001) from 78.8/100,000 (95 % CI 75.7, 82.0) to 179.9/100,000 (95 % CI 176.0, 183.8), the sex prevalence ratio increased from 2.27 to 2.78 (p < 0.001) and the peak prevalence age range increased from 45–49 to 55–59 years. MS incidence and prevalence in BC are among the highest in the world. Neither the incidence nor the incidence sex ratio increased over time. However, the prevalence and prevalence sex ratio increased significantly during the 18-year period, which may be explained by the increased peak prevalence age of MS, longer survival with MS and the greater life expectancy of women compared to men.
KW - Administrative health data
KW - Epidemiology
KW - Incidence
KW - Multiple sclerosis
KW - Prevalence
KW - Sex ratio
UR - http://www.scopus.com/inward/record.url?scp=84944514096&partnerID=8YFLogxK
U2 - 10.1007/s00415-015-7842-0
DO - 10.1007/s00415-015-7842-0
M3 - Article
C2 - 26205633
AN - SCOPUS:84944514096
SN - 0340-5354
VL - 262
SP - 2352
EP - 2363
JO - Journal of Neurology
JF - Journal of Neurology
IS - 10
ER -